Related references
Note: Only part of the references are listed.A phase II study of bevacizumab (BEV) plus erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic pancreatic cancer (MPC)
A. H. Ko et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603
E. M. O’Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy.
P. J. Hosein et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
Volker Heinemann et al.
GUT (2013)
Systemic treatment of advanced pancreatic cancer
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2012)
Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing
Christine A. Iacobuzio-Donahue et al.
CLINICAL CANCER RESEARCH (2012)
The Pancreas Cancer Microenvironment
Christine Feig et al.
CLINICAL CANCER RESEARCH (2012)
Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Igor A. Astsaturov et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Second-line chemotherapy with Capecitabine (Xeloda) and Docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
Ourania Katopodis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Salvage Therapy with Mitomycin and Ifosfamide in Patients with Gemcitabine-Resistant Metastatic Pancreatic Cancer: A Phase II Trial
Stefano Cereda et al.
CHEMOTHERAPY (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Uwe Pelzer et al.
EUROPEAN JOURNAL OF CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
Laetitia Dahan et al.
GUT (2010)
Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
Anna Novarino et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C. Yoo et al.
BRITISH JOURNAL OF CANCER (2009)
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
Seong Yoon Yi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
Chigusa Morizane et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
Brian M. Wolpin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study
Brett E. Fortune et al.
ONCOLOGY (2009)
Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers
Maria S. Pino et al.
ONCOLOGY (2009)
Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
Joanna M. Brell et al.
ONCOLOGY (2009)
Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions
Roland Andersson et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy
M. Reni et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses
A. Sultana et al.
BRITISH JOURNAL OF CANCER (2008)
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer
Henry Q. Xiong et al.
CANCER (2008)
Gemcitabine resistance in pancreatic cancer: Picking the key players
Michael P. Kim et al.
CLINICAL CANCER RESEARCH (2008)
A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study
U. Pelzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study
V. Heinemann et al.
ANNALS OF ONCOLOGY (2007)
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study
Akira Togawa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer:: a multicenter phase II trial
S. Boeck et al.
ANNALS OF ONCOLOGY (2007)
Identification of pancreatic cancer stem cells
Chenwei Li et al.
CANCER RESEARCH (2007)
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
M Reni et al.
BRITISH JOURNAL OF CANCER (2006)
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma -: Results of a phase II trial
E Mitry et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2006)
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
A Demols et al.
BRITISH JOURNAL OF CANCER (2006)
A Multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer
Michail Ignatiadis et al.
ONCOLOGY (2006)
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
N Tsavaris et al.
INVESTIGATIONAL NEW DRUGS (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients
HA Burris et al.
ONCOLOGIST (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
M Milella et al.
CANCER (2004)
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer
M Cantore et al.
ONCOLOGY (2004)
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
H Ulrich-Pur et al.
BRITISH JOURNAL OF CANCER (2003)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer
P Kozuch et al.
ONCOLOGIST (2001)
Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma
H Oettle et al.
ANTI-CANCER DRUGS (2000)
Share Paper
